Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro / Early erythropoietin use for the prevention of anemia in very low birth weight newborns
Rev. méd. Chile
;
128(12): 1313-7, dic. 2000. tab
Artículo
en Español
| LILACS
| ID: lil-281989
ABSTRACT
Background:
Anemia is common among very low birth weight newborns and requires frequent blood tranfusions. Erythropoietin was been reported to be useful in the prevention of this anemia.Aim:
To asses the benefits of early (before the third week of life) Human recombinant Erythropoietin (r-EPO) administration to reduce the requirement of blood tranfusions in very low birth weight newborns. Patients andmethods:
sixty newborns under 1500g of birthweight were randomly assigned to recive r-EPO (n=29) or placebo (n=31) three times per week, during four weeks. Packed red cell volume and reticulocyte counts were measured weekly. Serum erythropoietin was measured prior to eigth dose. Transfusion requirements were recorded.Results:
r-EPO reduced transfusions from 1.41 ñ 1.1 to 0.69 ñ 1 transfusions/newborns (p<0.001). At the fourth week of treatment, reticulocyte count was 14.8 ñ 7 and 6.4 ñ 4.9 percent in the active treatment group and placebo group respectively (p<0.001).Conclusions:
r-EPO reduces the requrement of transfusions in low birth weight infants
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Eritropoyetina
/
Enfermedades del Prematuro
/
Anemia Neonatal
Tipo de estudio:
Ensayo Clínico Controlado
Límite:
Femenino
/
Humanos
/
Masculino
/
Recién Nacido
Idioma:
Español
Revista:
Rev. méd. Chile
Asunto de la revista:
Medicina
Año:
2000
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS